Aptar Reports the US FDA Approval of Cardamyst (Etripamil) for PSVT

Shots:

• The US FDA has approved Aptar’s Cardamyst (Etripamil), developed by Milestone Pharmaceuticals, for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults
• Cardamyst (Intranasal) is a Bidose (BDS) Liquid Nasal Spray System
• Aptar collaborated with Milestone Pharmaceuticals to design a custom polypropylene container closure system with an integrated cap for Cardamyst

Ref: Businesswire |  Image: Mabwell | Press Release

Related News: HUTCHMED Reports NMPA’s NDA Acceptance with Priority Review of Savolitinib for Gastric Cancer Patients with MET Amplification

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com